LENZ THERAPEUTICS, INC. Debt Securities Available For Sale Excluding Accrued Interest
LENZ THERAPEUTICS, INC. (LENZ) had Debt Securities Available For Sale Excluding Accrued Interest of $195.79 million as of 2026-06-30, per its 10-Q filed 2026-08-11.
Financial Statements › Balance Sheet › Assets
us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest · last filed 2026-08-11
- 2026-06-30: Debt Securities Available For Sale Excluding Accrued Interest $195.79M.
- 2026-03-31: Debt Securities Available For Sale Excluding Accrued Interest $233.61M.
- 2025-12-31: Debt Securities Available For Sale Excluding Accrued Interest $267.17M.
- 2025-09-30: Debt Securities Available For Sale Excluding Accrued Interest $176.77M.
| Period end | Debt Securities Available For Sale Excluding Accrued Interest |
|---|---|
| 2026-06-30 | $195.79M 10-Q · filed 2026-08-11 |
| 2026-03-31 | $233.61M 10-Q · filed 2026-05-11 |
| 2025-12-31 | $267.17M 10-Q · filed 2026-08-11 |
| 2025-09-30 | $176.77M 10-Q · filed 2025-11-05 |
| 2025-06-30 | $171.91M 10-Q · filed 2025-07-30 |
| 2025-03-31 | $170.93M 10-Q · filed 2025-05-07 |
| 2024-12-31 | $188.87M 10-K · filed 2026-03-24 |
| 2023-12-31 | $30.65M 10-K · filed 2025-03-19 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |